(Q38265086)

1 September 2017

1 reference

title

How I treat newly diagnosed chronic myeloid leukemia in 2015. (English)

1 reference

Carlo Gambacorti-Passerini

1 September 2017

chronic myeloid leukemia

0 references

author

series ordinal

1

object named as

Carlo Gambacorti-Passerini

0 references

author name string

Rocco Piazza

series ordinal

2

1 reference

1 September 2017

24 November 2014

1 reference

American Journal of Hematology

1 September 2017

1 reference

1 September 2017

90

1 reference

1 September 2017

156-161

1 reference

1 September 2017

2

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 September 2017

1 reference

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.

21 January 2018

1 reference

Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study

21 January 2018

1 reference

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008

21 January 2018

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

21 January 2018

1 reference

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

21 January 2018

1 reference

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

21 January 2018

1 reference

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

21 January 2018

1 reference

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

21 January 2018

1 reference

Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.

21 January 2018

1 reference

21 January 2018

1 reference

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

21 January 2018

1 reference

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia

21 January 2018

1 reference

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?

21 January 2018

1 reference

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Dasatinib inhibits proinflammatory functions of mature human neutrophils

21 January 2018

1 reference

Pulmonary arterial hypertension in patients treated by dasatinib

21 January 2018

1 reference

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

21 January 2018

1 reference

Severe peripheral arterial disease during nilotinib therapy.

21 January 2018

1 reference

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

21 January 2018

1 reference

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.

21 January 2018

1 reference

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

21 January 2018

1 reference

Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients

21 January 2018

1 reference

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

21 January 2018

1 reference

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold

21 January 2018

1 reference

Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

21 January 2018

1 reference

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

21 January 2018

1 reference

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23887

1 reference

1 September 2017

1 reference

PubMed ID

25370814